Investor Alert: Pomerantz Law Firm Investigates Potential Securities Fraud at Beam Therapeutics
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices involving Beam Therapeutics Inc. (NASDAQ: BEAM) and certain of its officers or directors, on behalf of investors. The investigation was prompted by a September 8 press release from the company announcing updated clinical data for its gene therapy candidate, BEAM-302, which showed mixed results—while well-tolerated overall, it also revealed transient liver enzyme elevations in some patients. Following this news, Beam's stock price dropped $2.83 per share (9.54%) to close at $26.83 on September 8, 2026. The firm is inviting investors who may have been affected by the alleged misconduct or misleading disclosures to contact its legal team for potential inclusion in a class action. Pomerantz LLP has long specialized in corporate and securities litigation and claims numerous multimillion-dollar recoveries for clients over decades of practice.
Tickers: $BEAM
Topics: Beam Therapeutics clinical trial data investor claims stock price drop